Evidence map›Paper›PMID 35138678›Full record

ArticleJournal of the International AIDS Society2022

Early pre-exposure prophylaxis (PrEP) initiation and continuation among pregnant and postpartum women in antenatal care in Cape Town, South Africa.

Dvora Leah Joseph Davey, Rufaro Mvududu, Nyiko Mashele, Maia Lesosky, Nehaa Khadka, Linda-Gail Bekker, Pamina Gorbach, Thomas J Coates, Landon Myer

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the International AIDS Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 56 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 2 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03826199 phase4completednot on this map

Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town, South Africa (Formative Study)

TypeinterventionalSponsorUniversity of California, Los AngelesRan2019 to 2023Enrolled200ConditionsHivArmsTDF-FTC, Counselling on PrEP in antenatal and postnatal care
NCT03902418 completednot on this map

Evaluation of Pre-Exposure Prophylaxis (PrEP) Initiation, Retention, and Adherence in Pregnant and Breastfeeding Women

TypeobservationalSponsorUniversity of California, Los AngelesRan2019 to 2024Enrolled1,195ConditionsHIV-I InfectionArmsemtricitabine/tenofovir
3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Retention of clients in HIV oral pre-exposure prophylaxis care in Engela, Namibia.African journal of primary health care & family medicine · 2025
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Dvora Leah Joseph DaveyDepartment of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, USA.ORCID 0000-0001-6290-9293
Rufaro MvududuDivision of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Nyiko MasheleDivision of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Maia LesoskyDivision of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Nehaa KhadkaDepartment of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, USA.
Linda-Gail BekkerThe Desmond Tutu Health Foundation, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-0755-4386
Pamina GorbachDepartment of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, USA.
Thomas J CoatesDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Landon MyerDivision of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
University of Cape Town · ZAUniversity of California, Los Angeles · USDesmond Tutu HIV Foundation · ZA

Funding

UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Nina Thawata Harawa · 1997 to 2026
$53.5M
Evaluating the PrEP cascade in HIV-negative pregnant and breastfeeding women in South Africa (PrEP-PP)R01MH116771 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JOSEPH DAVEY, DVORA LEAH, MYER, BENJAMIN LANDON · 2018 to 2022
$2.5M
Evaluation of pre-exposure prophylaxis cascade in pregnant and breastfeeding women in Cape Town, South AfricaK01TW011187 · FIC · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JOSEPH DAVEY, DVORA LEAH · 2018 to 2022
$698k
FIC NIH HHS K01 TW011187FIC NIH HHS K01TW011187NIMH NIH HHS P30 MH058107NIMH NIH HHS R01 MH116771NIMH NIH HHS R01MH116771
6 · The paper itself

Abstract

introductionPre-exposure prophylaxis (PrEP) is a safe and effective prevention strategy to reduce women's risk of HIV in pregnancy and postpartum. Effective PrEP protection requires daily PrEP adherence, but little is known about maternal PrEP continuation and factors that influence PrEP use.

methodsThe PrEP in pregnancy and postpartum (PrEP-PP) study enrolled consenting pregnant, HIV-negative women at first antenatal care (ANC) visit with follow-up through 12 months postpartum. Eligible and consenting women and girls ≥16 years received HIV prevention counselling and were offered PrEP. Interviewers collected socio-demographic and behavioural data from participants at each visit. We analysed the proportion of women who initiated PrEP and the proportion who continued PrEP after 3 months with associated correlates by estimating the prevalence ratio adjusting for a priori confounders.

resultsBetween August 2019 and October 2021, we enrolled 1201 pregnant women (median gestation 21 weeks; age 26 years); 84% of women initiated PrEP at their first ANC visit (n = 1014); 55% were married or cohabiting. Overall, 66% of women on PrEP returned for a repeat prescription at 1 month; 58% returned at 3 months (n = 493 of 844). Almost one-half of women on PrEP reported a side effect at 1 month, mostly nausea/vomiting. Women on PrEP in the first and second trimesters had higher odds of reporting side effects (aOR 2.61; 95% CI 1.17-5.84) versus postpartum women. Women who reported side effects continued with PrEP less than those who did not report side effects (aPR = 0.87; 95% CI 0.77-0.97). Women with ≥1 previous pregnancy (aPR = 0.76; 95% CI 0.57-1.01) or were postpartum (aPR 0.85; 95% CI 0.75-0.97) were less likely to continue PrEP compared to women who were primigravid or pregnant. Women who reported having an HIV+ partner (aPR = 1.45; 95% CI 1.13-1.85) or high HIV risk perception (aPR = 1.20, 95% CI = 1.01-1.41) were more likely to continue on PrEP than those who had HIV-negative partners or low risk perception.

conclusionsPrEP initiation and early continuation were high in this setting, compared to other studies in women. Being postpartum and experiencing side effects were associated with lower PrEP continuation, presenting opportunities for counselling on early transient side effects. Interventions for postpartum women on PrEP are needed.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisAdultFemaleHumansPostpartum PeriodPregnancyPrenatal CareSouth AfricaAnti-HIV Agentsadherencebreastfeedingcohort studiespre-exposure prophylaxispregnantSouth Africa

Identifiers

PMID35138678
PMCPMC8826542
OpenAlexW4210838969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.